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Background. Severe human respiratory syncytial virus (hRSV) bronchiolitis in previously well infants may be due to differences
in the innate immune response to hRSV infection. Aim: to determine if factors mediating proposed mechanisms for severe
bronchiolitis differ with severity of disease. Methodology/Principle Findings. 197 infants admitted to hospital with hRSV
bronchiolitis were recruited and grouped according to no oxygen requirement (n=27), oxygen dependence (n=114) or
mechanical ventilation (n=56). We collected clinical data, nasopharyngeal aspirate (NPA) and if ventilated bronchoalveolar
lavage (BAL). Interferon-gamma (IFN-c), substance P (SP), interleukin 9 (IL-9), urea and hRSV load, were measured in cell free
supernatant from NPA and BAL. Multivariate analysis compared independent effects of clinical, virological and immunological
variables upon disease severity. IFN-c and SP concentrations were lower in NPA from infants who required oxygen or
mechanical ventilation. Viral load and IL-9 concentrations were high but did not vary with severity of disease. Independent
predictors of severe disease (in diminishing size of effect) were low weight on admission, low gestation at birth, low NPA IFN-c
and NPA SP. Nasal airway sampling appears to be a useful surrogate for distal airway sampling since concentrations of IFN-c,
SP, IL-9 and viral load in NPA correlate with the same in BAL. Conclusions. Our data support two proposed mechanisms for
severe hRSV disease; reduced local IFN-c response and SP mediated inflammation. We found large amounts of hRSV and IL-9 in
airways secretions from the upper and lower respiratory tract but could not associate these with disease severity.
Citation: Semple MG, Dankert HM, Ebrahimi B, Correia JB, Booth JA, et al (2007) Severe Respiratory Syncytial Virus Bronchiolitis in Infants Is Associated
with Reduced Airway Interferon Gamma and Substance P. PLoS ONE 2(10): e1038. doi:10.1371/journal.pone.0001038
INTRODUCTION
Human respiratory syncytial virus (hRSV) infection is ubiquitous
in infancy and it is the single most important cause of severe lower
respiratory tract infection in young children throughout the
world.[1] Severe disease (bronchiolitis or bronchiolitis pneumonia)
results in the hospital admission of approximately 2.5% of all
infants in industrialised countries making this virus the most
common cause for admission in the first year of life.[2] In
developing countries the morbidity and mortality associated with
hRSV infection is far greater.[3] Approximately 50% of infants
admitted to hospital with bronchiolitis suffer from recurrent
wheeze in later childhood.[4,5] It is unknown whether the
mechanism(s) associating severe bronchiolitis with recurrent
wheeze are a consequence of hRSV infection or due to an
inherent susceptibilities to both conditions.
The histopathology of severe bronchiolitis is small airway
obstruction due to viral-cytopathic epithelial disruption and de-
struction, parenchymal inflammatory-cell infiltration, luminal neu-
trophil migration and increased mucous production.[6,7] Mech-
anisms recently proposed to explain severe bronchiolitis include
reduced antiviral immunity (reduced IFN-c production), increased
viral replication, excessive ‘‘neurogenic inflammation’’ and elevated
IL-9-induced secretion of mucous.[8–11] These mechanisms are
based upon experimental studies in animals and observational
studies in well defined but relatively small groups of human infants.
In this large pragmatic clinical observational study, each
mechanism in this pathogenic pathway was tested by measuring
representative factors(IFN-c,viral load,Substance P andIL-9)inthe
respiratory secretions collected from infants admitted to hospital.
Our hypothesis is ‘‘where variation in a pathogenic mechanism
is associated with severe disease, representative factors (cytokines
and viral load) will vary with disease severity’’.
We studied the interactions and independent effects of these
factors upon disease severity by univariate and multivariate
analysis in previously well infants. Where associations were found
we compared the size of effect (relative odds ratio (ROR)) for each
measured factor with the size of effect for known clinical and
environmental risk factors for severe disease in the same groups of
infants.
Previous studies by our group have shown significant differences
in the disease characteristics and clinical course of hRSV
bronchiolitis between other-wise healthy infants born at term
and those born prematurely.[6,10,12] Because of these known
differences and expected over-representation of premature infants
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infants.
METHODS
Participants
Infants admitted with bronchiolitis to Alder Hey Children’s
Hospital, Liverpool during the winter seasons (November through
February) of 2002/3, 2003/4 and 2004/5 were recruited.
Bronchiolitis was diagnosed by paediatricians when infants
(children ,2 years old) presented with tachypnea (.50 breaths/
min), subcostal recession, and bilateral inspiratory crackles on
auscultation. hRSV status was established by a rapid antigen assay
of nasopharyngeal aspirate (NPA) described below. Only hRSV
antigen positive infants were included in this study. Criteria for
admission to the general wards include reduced oral intake (,75%
of normal) and/or oxygen saturation at ,93% in air. Oxygen was
administered to maintain oxygen saturation at .92%. Infants with
respiratory failure or significant apnoea who required mechanical
ventilation were admitted to the intensive care unit. Ventilated
infants were intubated using an uncuffed naso-tracheal tube, nasal
CPAP was not used.
Baseline data were collected at recruitment using a structured
history-form which included queries regarding a family history of
atopy in first degree relatives and current smoking by any
household member regardless of situation (Appendix S1). Pre-
mature (pre-term) birth was defined as birth before completion of
37 weeks gestation. Infants who had previously been admitted to
hospital or who had a history of haemodynamically significant
congenital cardiac disease were excluded.
Infants were retrospectively grouped according to the worst
severity of disease experienced during their admission using the
following criteria: ‘‘never any need for supplemental oxygen’’,
‘‘oxygen dependency at any time’’ and ‘‘any need for mechanical
ventilation’’.
Collection of Nasopharyngeal Aspirate (NPA)
NPA was collected by nursing staff as part of the diagnostic process
and for surveillance of community-acquired respiratory infections,
usually during the process of admission (,3 hrs) and always within
24 hours of admission. Infants were swaddled in a small blanket
and placed supine in a cot. Nasal secretions from both nostrils
were aspirated without lavage using a soft size 8F catheter with
two distal lateral eyes and a proximal side port for finger-tip
suction control (CARETIP
TM atraumatic-neonatal, Meddis Ltd
UK) connected to a conical trap (Tracheal suction set,
Unomedical Ltd UK) by medical vacuum (20 mmHg) while
advancing and withdrawing the catheter tip to a depth of
approximately 5 cm. The collection trap containing NPA was
taken to a laboratory and refrigerated (+4uC) for further
processing.
Collection of bronchoalveolar lavage
Non-bronchoscopic bronchoalveolar lavage (BAL) samples were
collected from ventilated infants by one of the investigators (MGS)
or a experienced respiratory physiotherapist, in accordance with
the European Respiratory Society 2000 guidelines and our earlier
studies.[10,13] A weight adjusted volume of 0.9% saline (1 ml/kg)
was instilled twice and then for a minimal dwell time to minimise
any urea dialysis effect.[14,15] It is not possible to collect BAL
from conscious non-intubated infants and we can not justify
anaesthetising infants with bronchiolitis only to collect BAL for
research purposes.
Detection of hRSV
NPA sample was diluted with 3 ml of sterile 0.9% saline, mixed
vigorously, and subjected to hRSV antigen enzyme linked
immunosorbent assay (ELISA) (BD Directigen RSV
TM; Becton
Dickinson UK). Residual NPA solution was refrigerated (+4uC) for
further processing.
Sample processing
BAL and residual NPA samples were filtered through nylon
monofilament gauze with a 60 mm pore size (Sefar Nitex 03-48/
31, Sefar Inc, Switzerland) to remove bulk mucus. The filtrate was
centrifuged at 300 g for 5 minutes at +4uC, the supernatant
removed, split into aliquots, and stored at 270uC.
Measurement of Urea
A well defined denominator used in a homogenous population
results in smaller coefficients of variation and a gain in precision of
the measurement.[16] Respiratory sample urea concentration was
used as a marker of sample quality and as denominator to adjust
for respiratory sample dilution during collection and process-
ing.[17] The urea dilution method for estimating dilution of
respiratory samples has recently been validated in studies of cats
and dogs.[18,19] Urea was measured using a sensitive urease
method with a minimum detection limit of 0.06 mmol/l (Randox
Laboratories Ltd, UK).[20] Respiratory samples were excluded
from further analysis where the urea concentration was less than
0.1 mmol/l, an arbitrary limit indicating excessive dilution.
Blood urea was only measured when there were concerns about
possible dehydration. Routine venesection is specifically not part of
the bronchiolitis care pathway of previously well infants at Alder
Hey Children’s Hospital and was not permitted by the ethics
committee for this research project. Blood urea was measured in
serum using a urease and glutamate dehydrogenase method
(COBAS INTEGRA 700H, Roche Diagnostics). Blood urea values
were collated when measured within 24 hr of admission.
Measurement of cytokines in NPA and BAL
IFN-c and SP were measured by ELISA (Diaclone, France and
R&D Systems Europe Ltd, UK) as per manufacturer’s instructions.
The assay was validated for measurement of IFN-c and SP in these
respiratory samples by a spiking and recovery experiment involving
addition and serial dilution of known amounts of IFN-c and SP in
a panel of 10 surplus samples (data not shown). Then further assays
ofIFN-c andSPina panelof 20respiratorysamples using increasing
dilutions of assay diluent. The optimum dilution of respiratory
samples for IFN-c was 1 in 2 and for SP was 1 in 10. The minimum
detection limit of IFN-c was 5 pg/ml and for SP 8 pg/ml. IL-9 was
measured using our validated in-house ELISA as described
previously.[10] The minimum detection limit of IL-9 was 80 pg/
ml. Cytokine concentrations in grouped data were compared ‘‘raw’’
and adjusted for dilution during sample collection and handling by
the urea dilution method described above.
Measurement of cell free hRSV load
Nucleic acid was extracted from 140 mL of filtered cell-free
respiratory sample using QIAamp
TM viral RNA MiniKit
TM
(Quiagen Ltd, UK). 10 mL of purified nucleic acid solution was
subject to reverse transcription using a hRSV specific primer as
previously described.[21] Two 1 mL samples of each cDNA
solution were subject in duplicate to 35 cycles of real time
polymerase chain reaction (RT-PCR) using primers specific to
a highly conserved region of the hRSV N gene and an Opticon
RSV Bronchiolitis Pathogenesis
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TM thermal cycler (Genetic Research Instrumentation Ltd., UK).
Quantification was based on gene-specific standard curves. hRSV
load is expressed as copies of N gene molecule per microlitre of
sample (copies/ml). Details in Appendix S1.
Statistics
A priori power calculations estimated that 16 participants were
required in each group to observe a difference of 1 standard deviation
(SD) (assuming 1 SD=30 pg/ml) between group geometric mean
cytokine concentrations with 80% power (a=0.05 and b=0.2).
Statistical analyses were performed using the software SPSS v13.0.1
(SPSS Inc. Illinois, USA). Clinical characteristics of participants were
compared by Pearson Chi-square test. Non-parametric cytokine data
were compared by Mann-Whitney U test. Normally distributed
cytokine and viral load data were compared by Student’s t-test after
validity was verified by Levene’s test. Univariate statistical tests were
two tailed and the p value is given when significant (p,0.05).
Pearsons correlation coefficient and the measure of goodness of fit of
the linear least-square model (R2) were calculated for group data in
paired samples. Multivariate binary logistical regression models were
constructed for two previously accepted definitions of severe disease
‘‘any need for supplemental oxygen including ventilation’’ and ‘‘any
need for mechanical ventilation’’ [11,22,23]. Co-variables included
ap r i o r iin the models were gender, birth-weight, gestation at birth,
corrected age on admission, weight on admission, family history of
atopy, exposure to environmental tobacco smoke, NPA concentra-
tions of SP, IFN-c, IL-9 and NPA hRSV load. History of apnoea was
excluded from the model as it isa criterion for mechanical ventilation.
Co-variables were rejected from the models where the effect was not
significant (p.0.1). The assumptions of the model were tested by
examination of the residuals and the overall fit of the model was
ascertained using the Hosmer and Lemeshow goodness of fittest.[24]
Ethics
The Liverpool Children’s Local Research Ethics Committee, an
independent statutory body, approved the study. Written informed
consent was obtained from all parents or carers.
RESULTS
Patient Characteristics
197 infants were recruited. Samples from 12 infants had urea
concentrations below 0.1 mmol/l and were excluded from further
analysis leaving 185 participants in the study. The distribution of
excluded cases between disease groups was not significant.
There were significant differences between groups (table 1).
There were significantly more prematurely born infants in the
ventilated group than the other two groups (p,0.01). The
ventilated group weighed less on admission, were younger (actual
age and age corrected for gestation at birth) and were born earlier
in gestation (all p,0.001). A significantly greater proportion of
infants in the ventilated group presented with apnoea (P,0.01).
Males were over-represented amongst all infants admitted with
bronchiolitis but the proportions between disease severity groups
did not differ significantly. There were no significant differences
between the disease groups with respect to gender, family history
of atopy, current smoking by any household member or duration
of illness prior to admission. One premature infant in each disease
group received intramuscular monoclonal anti-hRSV gamma-
globulin prior to admission.
Blood Urea
Blood urea was measured in 88 infants (no oxygen n=6/25,
oxygen dependent n=32/107, &ventilated n=50/53). Pooled
data from these infants was normally distributed (mean=
2.9 mmol/l, 2.5 to 97.5 percentile=1.0 to 5.8 mmol/l) and did
not differ significantly from the normal range for healthy infants
and young children aged 1 to 3 yr (n=50, mean=3.9 mmol/l,
2.5 to 97.5 percentile=1.8 to 6.0 mmol/l).[25] There were no
significant differences in blood urea between disease severity
groups. The clinical decision to bleed only these children who may
have been dehydrated might be expected to bias towards high urea
values but the data does not support this. We conclude that that
blood urea levels for this group of previously well infants
admitted with bronchiolitis were normal and that none were in
renal failure.
Table 1. Characteristics of participants.
..................................................................................................................................................
Characteristic
Worst Disease Severity during admission
No oxygen n=25 Oxygen n=107 Ventilation n=53
Male sex, n (%) 15, 60% 66, 62% 34, 64%
Premature birth (n) 7 19 24*
Term birth at (n) 18 88 29
Weight on admission(kg) 5.6 (4.9 to 7.3) 6.6 (4.8 to 8.2) 3.7 (3.0 to 4.8) **
Age on admission (weeks) 13 (7.9 to 21) 20 (11 to 32) 6.3 (4.2 to 13) **
Gestation (weeks) 40 (37 to 40) 40 (38 to 40) 37 (33 to 40) **
Corrected Age (weeks) 10 (6.1 to 18) 18 (8.8 to 32) 2.4 (20.1 to 6.9) **
Apnoea 6% 4% 31%*
Duration of illness (days) 4 (2 to 5) 3 (2 to 4) 3 (2 to 4)
Atopic family history 70% 65% 64%
Smoking in home 71% 79% 55%
Data are median and quartiles unless stated otherwise (Pearson X
2 two sided significance: *=p,0.01, **=p,0.001).
doi:10.1371/journal.pone.0001038.t001
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NPA concentrations of IFN-c, SP, and IL-9, in infants grouped by
disease severity are described without adjustment for sample
dilution in table 2. Data were not normally distributed. IFN-c
concentrations differed significantly between groups of infants who
never required oxygen and those who required oxygen (Mann-
Whitney U p=0.05) and those who required ventilation (p=0.04).
SP concentrations differed significantly between groups of infants
who never required oxygen and those who required ventilation
(p=0.04). There were no significant differences in IL-9 concen-
trations between groups.
Cytokine concentrations in each sample were adjusted by
division by the sample urea concentration to reflect dilution during
sample collection and handling. In grouped data this correction
resulted in normal distributions, smaller coefficients of variation
and a gain in the precision of the measurement, all of which
permitted comparison of data in smaller groups of infants.
Adjusted cytokine concentrations in term and preterm infants
grouped by disease severity are shown in figure 1 (expressed
natural log Ln([cytokine]/[urea]), ng/mol).
In term infants; significant differences (all p,0.05) were
observed between geometric mean IFN-c and SP concentrations
in the no oxygen group (IFN-c=48 ng/mol, SP=221 ng/mol)
and both the oxygen dependent (IFN-c=16 ng/mol, SP=42 ng/
mol) and ventilated groups (IFN-c=14 ng/mol, SP=29 ng/mol).
In preterm infants; no significant differences in SP and IFN-c
concentrations were observed between disease groups.
SP concentrations in ventilated term infants (29 ng/mol)
were significantly lower than in ventilated preterm infants
(231 ng/mol), p=0.02.
IL-9 concentrations did not differ significantly with disease
severity in term or preterm born infants.
We compared the concentrations of each cytokine (Ln([cyto-
kine]/[urea])) in paired NPA and BAL samples collected from
ventilated infants (figure 2). There were significant positive linear
correlations for each cytokine measured (Pearson correlation
coefficient (n&p value)); SP=0.39 (n=40, p=0.01), IFN-c=0.35
(n=38, p=0.03)&IL-9=0.46 (n=53, p=0.001) although there
was moderate scatter.
Viral load
NPA hRSV load quantified in 104 infants ranged from 4.36E+4t o
2E+11 copies/ml with a mean of 5E+9 copies/ml. A geometric
histogram of the data set was normally distributed. There were no
significant differences in hRSV load between 104 infants grouped
by disease severity or when sub-grouped by gestation at birth
regardless of whether the data compared were or were not
adjusted for dilution (figure 3).
The precision of the RT-PCR assay for samples measured in
duplicate was excellent (R
2=0.996, p,0.0001). There was
a significant positive linear correlation between hRSV load in 22
paired samples of NPA and BAL (data compared natural log
hRSV load/[urea], Pearson correlation coefficient=0.71,
R
2=0.55, p,0.001)) (figure 4).
Comparison was made between NPA hRSV load and concentra-
tionsofthecytokines(SP,IFN-c&IL-9)andinthesameNPAsample.
There was no association between NPA hRSV load and concentra-
tions of SP (n=99), IFN-c (n=100) or IL-9 (n=95) in NPA.
Analyses of independent effects
Multivariate binary logistical regression models predicting disease
severity were constructed using patient characteristics, adjusted NPA
cytokine concentrations and adjusted NPA hRSV load (table 3).
The Relative Odds Ratio (ROR) table gives the predicted
change in odds that a unit change in each Predictor Variable has
upon the outcome of the model (severe disease) relative to the
other Predictor Variables. The ROR value is a measure of the size
and direction of effect i.e. a value near 1 has little effect while
a value less than one indicates that an increase in the predictor
decreases the risk of severe disease. The ROR table permits
comparison of the size of effect that independent clinical and
immunological factors have upon risk of severe disease.
Table 2. NPA concentrations of IFN-c, SP, and IL-9
(unadjusted) by disease group.
......................................................................
No oxygen Oxygen Ventilated
IFN-c (pg/ml) 30 (64) 7.0 (44) * 1 (30) *
SP (pg/ml) 211 (307) 130 (421) 72 (323) *
IL-9 (pg/ml) 112 (1389) 210 (994) 113 (471)
Data are medians (interquartile range)). Mann-Whitney U test *=significant
difference at p,0.05 between No oxygen group.
doi:10.1371/journal.pone.0001038.t002
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Figure 1. Nasopharyngeal concentrations of IFN-c, SP, and IL-9 (expressed Ln([cytokine]/[urea]), ng/mol, geometric mean and 95% confidence
intervals), in 185 infants grouped by severity of bronchiolitis and sub-grouped by term (solid lines) or preterm birth (dashed lines). Horizontal
bars indicate between group comparisons by t-test and calculated p values.
doi:10.1371/journal.pone.0001038.g001
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strongest independent predictor (lowest ROR) of severe disease by
both definitions followed by reduced gestation at birth. Low NPA
concentrations of SP and IFN-c were significant independent
predictors of severe disease as defined by ‘‘need for supplemental
oxygen’’ with a similar ROR. Low NPA concentrations of SP and
IFN-c were associated with ‘‘need for ventilation’’ but the ROR
were closer to 1 and for IFN-c was not statistically significant.
DISCUSSION
Principal Findings
Severe disease (whether defined by need for oxygen or need for
mechanicalventilation)wasassociatedwithreduced IFN-cand SPin
the airways. There was high viral load and high IL-9 in infants with
severe disease but the measured amounts of both factors were not
different from those in infants who never required supplemental
oxygen. Further analysis of data with adjustment for sample dilution
demonstrated that the reduction in IFN-c and SP in infants with
severe disease was only observed in term-born infants.
Nasal airway sampling appears to be a useful surrogate for distal
airway sampling since concentrations of IFN-c, SP, IL-9 and viral
load in NPA correlate with the same in BAL.
Multivariate analysis identified (in order of size of effect) low
weight on admission, low gestation at birth, low NPA IFN-c and
low NPA SP as being significant independent predictors of severe
disease. Gender, family history of atopy, exposure to environmen-
tal tobacco smoke, NPA viral load and NPA IL-9 did not vary with
disease severity on univariate or multivariate analysis.
Strengths and limitations of this study
Particular strengths of this study include the following features.
This is a pragmatic study of a large number of previously well
human infants sampled during routine care. Exclusions were
limited which exposed the study to clinical heterogeneity. While
heterogeneity is recognised to make small differences between
groups harder to detect, when differences are observed they are
more likely to be real.[26] The findings of this study are therefore
generally applicable to most infant populations in industrialised
countries. Clinical details and respiratory samples were collected in
a systematic way. Patients in different disease groups were sampled
at the same times in the course of their disease. Most samples were
Figure 2. Scatter plot and best fit line between IFN-c, SP and IL-9 concentrations (expressed Ln([cytokine]/[urea]), ng/mol) in paired samples of
NPA and BAL. Pearson correlation coefficient: SP=0.39 (n=40, p=0.01), IFN-c=0.35 (n=38, p=0.03)&IL-9=0.46 (n=53, p=0.001).
doi:10.1371/journal.pone.0001038.g002
Figure 3. Cell-free hRSV load (expressed Ln(hRSV load/urea),
geometric mean and 95% confidence intervals), in the nasopharyn-
geal aspirate of 104 infants grouped by worst severity of
bronchiolitis during hospital admission and sub-grouped by term
(solid lines) or preterm birth (dashed lines).
doi:10.1371/journal.pone.0001038.g003
Figure 4. Scatter plot and best fit line between hRSV load (natural
log hRSV load/[urea]) in 22 paired samples of NPA and BAL, Pearson
correlation coefficient=0.71 (R
2=0.55, p,0.001).
doi:10.1371/journal.pone.0001038.g004
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that our observations are artefacts induced by hospital treatment
or mechanical ventilation. Correcting for sample dilution using
sample urea improved the precision of measured factors. The
study was sufficiently powered to allow univariate comparisons
between term and preterm born infants and a multivariate analysis
of clinical and immunological factors.
Limitations of the study include the following points. For
pragmatic and ethical reasons sampling was limited to those
secretions which are readily available in the clinical setting. There
is no healthy control group for this type of study as well infants are
not coryzal and have insufficient nasal secretions for direct
aspiration.[9] Our conclusions are limited to comparisons between
hospitalised previously well infants grouped by severity of hRSV
disease. Ethical reasons also prevented collection of a complete
data set for blood urea values, so respiratory sample urea alone
was used to correct for sample dilution.
Relationship of this study to others
IFN-c induces protective cellular responses against viral infections
and inhibits the proliferation of smooth muscles cells, endothelial
cells and the synthesis of collagens by myofibroblasts.[27,28]
Reduced interferon production has been proposed as a permissive
mechanism for severe respiratory virus infection and asthma
exacerbations in humans.[29] Bont et al described low nasopha-
ryngeal IFN-c concentrations in 17 ventilated infants compared
with 43 non-ventilated infants but warned that over-representation
of premature born infants in the ventilated group may have
introduced bias.[9] Our data confirms Bont et al’s important
finding and clarifies that the low airway IFN-c response is
restricted to previously healthy term-born infants. The non-
structural proteins of hRSV antagonise the human interferon
system allowing subversion of one element of the early innate
immune response to the advantage of the virus.[30] Any inherent
normal variation of airway interferon response within a population
of otherwise healthy term born infants would be expected to
predispose a minority of infants to severe disease. This inherent
variation could also explain the very strong association between
severe hRSV disease in infancy and the association with recurrent
wheezing in childhood which is invariably seen in conjunction
with viral respiratory infections and is independent of atopic
status.[4,5,31]
Reduced local interferon concentrations would be expected to
permit increased viral replication, greater cytopathic effects and
increased shedding into the respiratory tract. De Vincenzo et al
described a relationship between hRSV load and disease severity
using plaque assays and a multivariate analysis.[11] The relation-
ship was not strong and like our data was not found on univariate
analysis. In our study both forms of analysis rejected hRSV load
on day of admission as predicting disease severity. Our finding
agrees with three other studies which measured viral load by
plaque assay and reverse transcribed RT-PCR though some of
these studies may have been underpowered and all were restricted
to univariate analysis.[11,32–34] In the studies by Perkins et al
(RT-PCR, 36 infants) and Wright et al (plaque assay, 17 infants),
viral load in nasal washes decreased over the first few days of
admission at a time when the clinical manifestations of hRSV
disease were worsening.[33,35]
Like Wright and Perkins we observed a strong linear relation-
ship between hRSV load in the upper and lower airways of
individuals across a range of six magnitudes with some
scatter.[33,35] This suggests that our method like theirs makes
a valid measurement of total virus shed from a respiratory tract
that behaves as a continuum. We chose not to use plaque assays in
this study which recruited just under 200 infants over 3 winter
epidemics. Plaque assays are laborious and need fresh samples.
Co-circulating hRSV strains vary year on year and have very large
differences in tropism in plaque assays.[35]
We do not dismiss the likelihood that viral load at an earlier
time point is a predictor of disease severity, or that viral load would
be a predictor of disease severity if comparison were made
between some of the great majority of infants who are not
hospitalised (97.5%) and the minority that are.
To our knowledge the role of endogenous SP has not been
investigated in the airways of human infants. Massive neutrophil
migration into the airways is a characteristic feature in severe
hRSV bronchiolitis.[6,36] ‘‘Neurogenic inflammation’’ mediated
by the neurokinin SP is one mechanism proposed for neutrophil
recruitment and smooth muscle contraction in the airways of
hRSV infected weanling rats.[8,37] Exogenous SP has potent pro-
inflammatory cytokine effects in mouse and human airway
studies.[38,39] The finding of lower concentrations of SP in the
cell free airway fluid of term infants with severe disease is therefore
surprising. However it is congruent with the reports of up-
regulation of the high affinity SP receptor in lung tissue from RSV
infected weanling rats by Piedimonte and King.[8,37] The finding
also compliments Piedimonte’s more recent description of reduced
neurotrophin in the cell free supernatant of human infant BAL
and increased expression of the neurotrophin receptor in the
cellular fraction of human infant BAL.[40] Blockade of the SP
receptor in hRSV infected weanling rats reduces apnoea.[41,42]
hRSV infection in human infants is associated with apnoea and
sudden infant death. Our data supports the hypothesis that SP
plays a role in the mechanism of hRSV disease.
McNamara et al described large quantities of IL-9 in the lower
airways of infants with severe bronchiolitis and discovered that
neutrophils were the source.[10] IL-9 induces mucous cell
Table 3. Independent variables predicting severe hRSV Bronchiolitis (two definitions) in 185 participants by multivariate binary
logistical regression.
..................................................................................................................................................
Predictor Variable
Any need for supplemental oxygen, including ventilation. Any need for mechanical ventilation.
Relative Odds Ratio (95%CI) Significance (p) Relative Odds Ratio (95%CI) Significance (p)
Admission Weight (kg) 0.016 (0.001–0.274) 0.004 0.018 (0.001–0.383) ,0.001
Gestation (weeks) 0.482 (0.287–0.812) 0.006 0.537 (0.357–0.808) 0.003
NPA IFN-c (ng/mol) 0.724 (0.568–0.923) 0.009 0.857 (R) (0.680–1.059) 0.19 NS
NPA SP (ng/mol) 0.744 (0.615–0.900) 0.002 0.861 (0.740–1.002) 0.054
Predictor Variables included in models but rejected (R) where the Relative Odds Ratio was not independent or significant (NS, P.0.1) included gender, birth-weight,
corrected age on admission, family history of atopy, exposure to environmental tobacco smoke, and adjusted NPA concentrations of both IL-9 and hRSV load.
doi:10.1371/journal.pone.0001038.t003
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and airway hyper-responsiveness.[43–45] Genetic linkage studies
in humans indicate that IL-9 plays an important role in the
pathogenesis of atopic asthma.[46] In earlier studies we were
unable to determine if airway concentrations of IL-9 varied with
hRSV disease severity because we only examined the bronch-
oalveolar fluid from ventilated infants. We found large amounts of
IL-9 in both the upper and lower airway secretions but did not
observe any association with disease severity.
McNamara et al reported striking differences in the cellular and
pro-inflammatory and anti-inflammatory responses in BAL
between term and prematurely born infants ventilated for severe
hRSV bronchiolitis.[6,12] Premature birth affects the functional
development of the lung resulting in reduced alveolar formation,
impaired gas mixing and low lung volumes.[47] Preterm infants
would be expected to require less airway obstruction than term
infants to reach the compromised physiological state that requires
oxygen or ventilation. Severe bronchiolitis in previously healthy
preterm infants need not involve any relative difference in
immunity but instead simply reflect a degree of reduced lung
function.[48] This is evident from the multivariate analysis which
found strong independent associations between low weight on
admission and low gestation with severe disease. Both these
predictor variables are markers of lung growth and function. In
comparison, term infants with appropriately developed airways
are more physiologically robust. In term infants, differences in the
innate immune system (reduced IFN-c synthesis and possibly
increased SP uptake) differentiate those infants who experience
severe disease from those who are less affected.
Meaning of this study
Our data directly supports two of the recently proposed
mechanisms for severe hRSV disease, namely a reduced local
IFN-c response and SP mediated inflammation. We have found
large amounts of hRSV and IL-9 in airways secretions from the
upper and lower respiratory tract but could not associate absolute
amounts with disease severity.
A difference in the innate response to primary hRSV infection,
common to term infants susceptible to severe hRSV bronchiolitis,
may explain why so many of these infants experience recurrent
wheeze in childhood in association with viral respiratory tract
infections.
SUPPORTING INFORMATION
Appendix S1 Detailed Methods and Structured History Ques-
tionaire.
Found at: doi:10.1371/journal.pone.0001038.s001 (0.03 MB
DOC)
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